Write your message
Volume 7, Issue 1 (Winter 2022)                   J Obstet Gynecol Cancer Res 2022, 7(1): 32-37 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Behnamfar F, Rouholamin S, Allameh T S, Sabet F, Mousavi Seresht L, Nazemi M. Comparative Study of Laparascopy Scoring and Laparatomy Staging in Advance Ovarian Cancer. J Obstet Gynecol Cancer Res. 2022; 7 (1) :32-37
URL: http://jogcr.com/article-1-429-en.html
1- Department of Obstetrics and Gynecology (Women’s Oncology), Isfahan University of Medical Science, Isfahan, Iran
2- Department of Obstetrics and Gynecology (Women's Laparoscopy), Isfahan University of Medical Science, Isfahan, Iran
3- Department of Obstetrics and Gynecology (Women’s Oncology), Isfahan University of Medical Science, Isfahan, Iran , maryamnazemi2012@yahoo.com
Abstract:   (140 Views)
Background & Objective: Comparative study between laparoscopic and laparotomy scoring in patients with advanced ovarian cancer.
Materials & Methods: This prospective study included 27 patients with advanced ovarian cancer who underwent laparoscopy and laparotomy scoring at hospitals affiliated with Isfahan University of Medical Sciences (IUMS) during 2020 and 2021. The laparoscopic predictive index value (PIV) score (range: 0-14) was calculated for all patients. In patients with PIV scores <8, primary cytoreductive surgery (PCS) was performed, and patients with scores ≥8 were candidates for neoadjuvant chemotherapy (NACT). In the PCS group, laparotomy scoring and surgical findings for each anatomical area were registered for all patients, and concordance between laparoscopy and laparotomy findings was compared. Residual disease following PCS was documented for all patients.
Results: A total of 27 patients underwent laparoscopic scoring surgery; 25 patients (92/5%) had a PIV score <8, and two patients (7/5%) had a PIV score ≥8. There was 92% agreement between PIV scores at laparoscopy and laparotomy. Agreements in different anatomical regions in laparoscopy and laparotomy were as follows: involvement of the bowel 76%, mesenteric 92%, liver 96%, omental 92%, diaphragm 96%, stomach 100%, peritoneal carcinomatosis 96%. A laparoscopic PIV score of <8 had a PPV of 84% at predicting R0 at PCS.
Conclusion: Laparoscopic scoring is a precise approach in the management of patients with advanced ovarian cancer. Laparoscopic scoring is a screening method of selecting patients for primary surgery or NACT and improved R0 resection at PCS. The present study was designed to assess patients who would gain the maximum benefits from primary surgery.
Full-Text [PDF 481 kb]   (8 Downloads) |   |   Full-Text (HTML)  (14 Views)  
Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2021/06/19 | Accepted: 2021/07/12 | Published: 2021/09/9

References
1. Openshaw MR, Fotopoulou C, Blagden S, Gabra H. The next steps in improving the outcomes of advanced ovarian cancer. Womens Health (Lond). 2015;11(3):355-67. [DOI:10.2217/WHE.15.6]
2. SEER N. SEER cancer statistics factsheets: Ovary cancer. 2014.
3. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(28):3460-73. [DOI:10.1200/JCO.2016.68.6907]
4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-44. [DOI:10.1002/cncr.24149]
5. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100(1):33-7. [DOI:10.1016/j.ygyno.2005.07.123]
6. Brockbank EC, Ind TE, Barton DP, Shepherd JH, Gore ME, A'Hern R, et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14(1):42-50. [DOI:10.1136/ijgc-00009577-200401000-00005]
7. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study. Gynecol Oncol. 2008;108(2):265-70. [DOI:10.1016/j.ygyno.2007.11.002]
8. Salani R, Bristow RE. Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol. 2012;55(1):75-95. [DOI:10.1097/GRF.0b013e31824b4629]
9. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10-4. [DOI:10.1016/j.ygyno.2011.08.014]
10. Fagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013;131(2):341-6. [DOI:10.1016/j.ygyno.2013.08.005]
11. Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol. 2014;134(3):462-7. [DOI:10.1016/j.ygyno.2014.07.004]
12. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199(6):642 e1-6. [DOI:10.1016/j.ajog.2008.06.052]
13. Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hrobjartsson A, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol. 2011;64(1):96-106. [DOI:10.1016/j.jclinepi.2010.03.002]
14. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, et al. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018;151(3):428-32. [DOI:10.1016/j.ygyno.2018.10.017]
15. Shivkumaran S, Mandakulutur G, Banavara K. Role of staging laparoscopy to evaluate feasibility of performing optimal cytoreductive surgery in epithelial ovarian cancers. Int J Res Med Sci. 2016;4:5099-102. [DOI:10.18203/2320-6012.ijrms20164062]
16. Rutten MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, Naaktgeboren CA, van Gorp T, et al. Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial. J Clin Oncol. 2017;35(6):613-21. [DOI:10.1200/JCO.2016.69.2962]
17. van de Vrie R, Rutten MJ, Asseler JD, Leeflang MM, Kenter GG, Mol BWJ, et al. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. Cochrane Database Syst Rev. 2019;3(3):CD009786. [DOI:10.1002/14651858.CD009786.pub3]
18. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, et al. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018;132(3):545-54. [DOI:10.1097/AOG.0000000000002796]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.